7/29, 8:07 AM (Source: TeleTrader)
more TeleTrader news

AstraZeneca's Q2 revenue rises 31% to $8.2B

AstraZeneca plc revealed on Thursday that its second-quarter revenue came in at $8.2 billion, having surged 31% compared to the last year's second trimester.

The company noted its reported earnings per share (EPS) in the second quarter landed at $0.42, while core EPS amounted to $0.9 after having lost 27% and 6% year on year, respectively. The revenue excluding the contributions from COVID-19 vaccine sales went up by 17% in the second trimester.

"AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas, particularly Oncology, New CVRM and Fasenra in Respiratory. As a result, we have delivered further earnings progression, supported ongoing launches, and continued our investment in R&D," company CEO Pascal Soriot commented.

Breaking the News / BU